Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
37.98
-0.20 (-0.52%)
4:05:27 PM EDT: $37.95 -0.03 (-0.08%)
Products

U.S. FDA Approves Pfizer's Xeljanz For Treatment Of Active Polyarticular Course Juvenile Idiopathic Arthritis

Published: 09/28/2020 21:30 GMT
Pfizer Inc (PFE) - U.S. FDA Approves Pfizer’s Xeljanz® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis.
Pfizer Inc - Xeljanz Oral Solution is Anticipated to Be Available by End of Q1 2021.